B O O K - American College of Rheumatology
B O O K - American College of Rheumatology
B O O K - American College of Rheumatology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
REF Industry Roundtable-supported Symposia<br />
6:30 – 7:00 pm<br />
Registration and Dinner<br />
7:00 – 7:05 pm<br />
Welcome and Overview<br />
Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />
7:05 – 7:25 pm<br />
Overview <strong>of</strong> Chronic Pain Associated with Rheumatic Diseases<br />
Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />
7:25 – 7:55 pm<br />
The Pathophysiology <strong>of</strong> Chronic Pain<br />
Daniel J. Clauw, MD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />
7:55 – 8:25 pm<br />
The Pharmacological and Nonpharmacological Management <strong>of</strong> Chronic<br />
Pain in Rheumatic Diseases<br />
Mary-Ann Fitzcharles, MB, ChB, MRCP (UK) FRCP(C);The Pain Centre, McGill<br />
University Health Centre; Montreal, Quebec, Canada<br />
8:25 – 8:35 pm<br />
Applying the Evidence: A Case-based Discussion<br />
Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />
8:35 – 9:00 pm<br />
Question and Answer Session<br />
6:30 – 9:30 pm CME-Accredited Symposium<br />
For CME-accredited symposia, the sponsoring organization is responsible for<br />
panning and providing CME credit.<br />
Atlanta Marriott Marquis, Marquis Ballroom<br />
Advances in the Treatment <strong>of</strong> Systemic Lupus Erythematosus Learning<br />
Continuum<br />
Sponsored by Cleveland Clinic<br />
Supported by an educational grant from Human Genome Sciences, Inc.<br />
Physician (ACCME) Accreditation Statement<br />
This activity has been planned and implemented in accordance with the<br />
Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />
Medical Education (ACCME) through the sponsorship <strong>of</strong> the Cleveland<br />
Clinic. The Cleveland Clinic Foundation Center for Continuing Education<br />
is accredited by the ACCME to provide continuing medical education for<br />
physicians.<br />
Credit Designation Statement<br />
The Cleveland Clinic Foundation Center for Continuing Education designates<br />
this educational activity for a maximum <strong>of</strong> 2.0 AMA PRA Category 1<br />
Credit(s). Physicians should only claim credit commensurate with the<br />
extent <strong>of</strong> their participation in the activity.<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Review the efficacy and safety data <strong>of</strong> current treatments for systemic<br />
lupus erythematosus<br />
• List the biologic evidence base for B-cell depletion and discuss its<br />
potential application to systemic lupus erythematosus therapy<br />
• Discuss the biologic and clinical trial data for BAFF and describe their<br />
implications for clinical practice<br />
6:30 – 7:30 pm<br />
Registration and Dinner<br />
7:30 – 7:40 pm<br />
Introduction – Lupus: a Historical Perceptual<br />
Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />
7:40 – 8:00 pm<br />
The Historical Problems <strong>of</strong> SLE Study Design<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
8:00 – 8:20 pm<br />
The Current Status <strong>of</strong> the Treatment <strong>of</strong> Lupus Nephritis<br />
David Jayne, MD; Addenbrooke’s Hospital; Cambridge, England<br />
8:20 – 8:40 pm<br />
B-Cell Targeting in SLE: Is B-Cell Depletion or Modulation Effective?<br />
Marc Levesque, MD, PhD; University <strong>of</strong> Pittsburgh Medical Center;<br />
Pittsburgh PA<br />
8:40 – 9:00 pm<br />
B-Cell Activating Factor (BAFF) in SLE: Biologic and Clinical Data<br />
W. Winn Chatham, MD; University <strong>of</strong> Alabama at Birmingham School <strong>of</strong><br />
Medicine; Birmingham, AL<br />
9:00 – 9:30 pm<br />
Panel Discussion and Questions<br />
wednesday, NOVEMBER 10, 2010<br />
The event listed below is a non-CME Program wholly sponsored and<br />
supported by Amgen. By holding the Program, Amgen has represented that<br />
the Program has been developed and will be implemented in accordance<br />
with the requirements <strong>of</strong> the FDA and applicable standards <strong>of</strong> the PhRMA<br />
Code on Interactions with Healthcare Pr<strong>of</strong>essionals. Amgen is to observe all<br />
guidelines established by federal and state regulatory agencies regarding<br />
non-CME educational or promotional presentations throughout the duration<br />
<strong>of</strong> the Program. The content and views expressed during the Program are<br />
those <strong>of</strong> Amgen and presenters. The ACR by making this venue available<br />
does not guarantee, warrant or endorse the content <strong>of</strong> the Program nor the<br />
products discussed and reviewed during the Program.<br />
6:30 – 9:30 pm Non-CME Accredited Symposium<br />
Omni at CNN Center, Grand Ballroom<br />
Prolia (denosumab): A New Approach in the Treatment <strong>of</strong> Postmenopausal<br />
Osteoporosis in Women at High Risk for Fracture<br />
Developed and <strong>of</strong>fered by Amgen<br />
6:30 – 7:15 pm<br />
Registration and Dinner<br />
7:15 – 7:35 pm<br />
The Prolia (denosumab) Innovation<br />
Nelson B. Watts, MD; University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine;<br />
Cincinnati, OH<br />
7:35 – 8:15 pm<br />
Introducing Prolia (denosumab)<br />
Speaker to be announced<br />
8:15 – 9:00 pm<br />
Question and Answer<br />
282<br />
2010 Program Book
Change language